UY27795A1 - Inducción de tolerancia inmunológica específica de antígeno - Google Patents

Inducción de tolerancia inmunológica específica de antígeno

Info

Publication number
UY27795A1
UY27795A1 UY27795A UY27795A UY27795A1 UY 27795 A1 UY27795 A1 UY 27795A1 UY 27795 A UY27795 A UY 27795A UY 27795 A UY27795 A UY 27795A UY 27795 A1 UY27795 A1 UY 27795A1
Authority
UY
Uruguay
Prior art keywords
tolerogen
specific immune
host
immune tolerance
antigen specific
Prior art date
Application number
UY27795A
Other languages
English (en)
Inventor
Emil D Kakkis
Merry Passage
Christopher Tanaka
Thomas Lester
Rebecca Yang
Original Assignee
Harbor Ucla Res & Education
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Harbor Ucla Res & Education filed Critical Harbor Ucla Res & Education
Publication of UY27795A1 publication Critical patent/UY27795A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A61K31/522—Purines, e.g. adenine having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7024—Esters of saccharides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08—Peptides having 5 to 11 amino acids
    • A61K38/095—Oxytocins; Vasopressins; Related peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
    • A61K38/13—Cyclosporins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pulmonology (AREA)
  • Molecular Biology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Transplantation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)

Abstract

Se induce la tolerancia inmunológica específica en un anfitrión mamífero mediante la administración de un tolerágeno en combinación con un régimen de inmunosupresión. Los métodos incluyen, opcionalmente, un período de acondicionamiento previo, durante el cual se administran agentes inmunosupresores en ausencia del tolerágeno.Después del régimen de tolerización, se descontinúa la administración al anfitrión de los agentes supresores, pero el anfitrión es capaz de mantener tolerancia inmunológica específica a los antigénicos determinantes presentes en el tolerágeno. Óptimamente, el tolerágeno tendrá propiedades de alta captación que permiten la captación in vivo a concentraciones bajas en una extensa variedad de tipos celulares tolerizante.
UY27795A 2002-05-06 2003-05-06 Inducción de tolerancia inmunológica específica de antígeno UY27795A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US10/141,668 US7485314B2 (en) 2002-05-06 2002-05-06 Induction of antigen specific immunologic tolerance

Publications (1)

Publication Number Publication Date
UY27795A1 true UY27795A1 (es) 2003-11-28

Family

ID=29399718

Family Applications (1)

Application Number Title Priority Date Filing Date
UY27795A UY27795A1 (es) 2002-05-06 2003-05-06 Inducción de tolerancia inmunológica específica de antígeno

Country Status (16)

Country Link
US (3) US7485314B2 (es)
EP (1) EP1507555B1 (es)
JP (1) JP4933042B2 (es)
CN (1) CN100360182C (es)
AR (1) AR039882A1 (es)
AU (1) AU2003228829B2 (es)
BR (1) BR0309809A (es)
CA (1) CA2492394A1 (es)
ES (1) ES2401681T3 (es)
HK (1) HK1081438A1 (es)
IL (1) IL165016A (es)
MX (1) MXPA04009292A (es)
TW (1) TWI349556B (es)
UY (1) UY27795A1 (es)
WO (1) WO2003094840A2 (es)
ZA (1) ZA200409787B (es)

Families Citing this family (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7560424B2 (en) 2001-04-30 2009-07-14 Zystor Therapeutics, Inc. Targeted therapeutic proteins
US7629309B2 (en) 2002-05-29 2009-12-08 Zystor Therapeutics, Inc. Targeted therapeutic proteins
WO2003020039A1 (en) * 2001-08-28 2003-03-13 Rush-Presbyterian-St. Luke's Medical Center Immune tolerance to predetermined antigens
CA2484000A1 (en) * 2002-05-24 2003-12-04 Schering Corporation Neutralizing human anti-igfr antibody
US20050026823A1 (en) 2003-06-20 2005-02-03 Biomarin Pharmaceutical Inc. Use of the chaperone receptor-associated protein (RAP) for the delivery of therapeutic compounds to the brain and other tissues
WO2005002515A2 (en) 2003-06-20 2005-01-13 Biomarin Pharmaceutical Inc. Delivery of therapeutic compounds to the brain and other tissues
US7442372B2 (en) 2003-08-29 2008-10-28 Biomarin Pharmaceutical Inc. Delivery of therapeutic compounds to the brain and other tissues
EP1694850B1 (en) 2003-11-12 2011-06-29 Schering Corporation Plasmid system for multigene expression
PE20050928A1 (es) * 2003-11-21 2005-11-08 Schering Corp Combinaciones terapeuticas de anticuerpo anti-igfr1
US7811562B2 (en) * 2004-12-03 2010-10-12 Schering Corporation Biomarkers for pre-selection of patients for anti-IGF1R therapy
CA2596332A1 (en) * 2005-02-04 2006-08-10 Dow Agrosciences, Llc Anti-t cell and autoantigen treatment of autoimmune disease
AU2006236637B2 (en) * 2005-04-15 2012-09-06 Merck Sharp & Dohme Corp. Methods and compositions for treating or preventing cancer
KR20080019249A (ko) * 2005-06-15 2008-03-03 쉐링 코포레이션 안정한 항체 제형
WO2007035716A2 (en) 2005-09-16 2007-03-29 Raptor Pharmaceutical Inc. Compositions comprising receptor-associated protein (rap) variants specific for cr-containing proteins and uses thereof
WO2008125903A2 (en) * 2006-12-12 2008-10-23 Chaim Sheba Medical Center Method of inhibiting an undesired immune response
JP2010524849A (ja) * 2007-03-21 2010-07-22 ラプトール ファーマシューティカル インコーポレイテッド 環状受容体関連蛋白ペプチド
JP5627571B2 (ja) 2008-05-07 2014-11-19 バイオマリン ファーマシューティカル インコーポレイテッド リソソーム標的化ペプチドおよびその使用
EP2475376B1 (en) 2009-06-17 2016-03-30 BioMarin Pharmaceutical Inc. Formulations for lysosomal enzymes
CA2778669C (en) * 2009-10-27 2019-04-16 Erytech Pharma Composition to induce specific immune tolerance
KR102040867B1 (ko) * 2010-10-27 2019-11-07 박스알타 인코퍼레이티드 면역 관용 유도 및 면역진단을 위한 ｆｖｉｉｉ 펩타이드
CA2834532A1 (en) 2011-04-29 2012-11-01 Selecta Biosciences, Inc. Tolerogenic synthetic nanocarriers to reduce cytotoxic t lymphocyte responses
PE20140469A1 (es) * 2011-05-16 2014-04-23 Genzyme Corp Induccion de tolerancia inmunologica utilizando metotrexato
CA2863329C (en) 2012-01-12 2023-01-03 Biogen Idec Ma Inc. Methods of reducing immunogenicity against factor viii in individuals undergoing factor viii therapy
US20150071967A1 (en) * 2012-04-02 2015-03-12 University Of Bristol Tolerisation-Inducing Composition
CN106668852B (zh) * 2012-04-13 2020-12-25 艾棣维欣(苏州)生物制药有限公司 一种治疗和/或预防ⅰ型糖尿病的组合物及其应用
ES2679374T3 (es) 2012-11-27 2018-08-24 Biomarin Pharmaceutical Inc. Proteínas de fusión terapéuticas dirigidas de enzima lisosómica y usos de las mismas
US10357482B2 (en) 2013-05-03 2019-07-23 Selecta Biosciences, Inc. Methods providing a therapeutic macromolecule and synthetic nanocarriers comprising immunosuppressant locally and concomitantly to reduce both type I and type IV hypersensitivity
EP3622821A1 (en) * 2013-05-15 2020-03-18 Regents of the University of Minnesota Adeno-associated virus mediated gene transfer to the central nervous system
KR20240123409A (ko) 2014-09-07 2024-08-13 셀렉타 바이오사이언시즈, 인크. 유전자 편집 항-바이러스 전달 벡터 면역 반응을 약화시키기 위한 방법 및 조성물
EP3344575B1 (en) 2015-09-04 2020-04-15 SQZ Biotechnologies Company Intracellular delivery of biomolecules to cells comprising a cell wall
CA3003750A1 (en) 2015-11-06 2017-05-11 Biomarin Pharmaceutical Inc. Cell-based assays for detection of antibodies or other factors that neutralize uptake of lysosomal enzymes
AU2017250298A1 (en) 2016-04-15 2018-10-11 The Trustees Of The University Of Pennsylvania Gene therapy for treating mucopolysaccharidosis type II
AU2018236123B2 (en) 2017-03-11 2024-04-18 Selecta Biosciences, Inc. Methods and compositions related to combined treatment with anti-inflammatories and synthetic nanocarriers comprising an immunosuppressant
AU2018335752A1 (en) 2017-09-22 2020-03-12 Christian HINDERER Gene therapy for treating Mucopolysaccharidosis type ii
WO2019245038A1 (ja) * 2018-06-22 2019-12-26 株式会社Ｊｕｎｔｅｎ Ｂｉｏ 複合状態を有する細胞混合物を用いた、免疫寛容を誘導する抗体、及び誘導されたリンパ球、また誘導されたリンパ球を用いる細胞治療剤及び治療法
CN113301925A (zh) 2018-12-19 2021-08-24 小利兰·斯坦福大学理事会 用于溶酶体靶向的双官能分子以及相关的组合物和方法

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4117118A (en) * 1976-04-09 1978-09-26 Sandoz Ltd. Organic compounds
US5135915A (en) * 1988-10-14 1992-08-04 Genentech, Inc. Method for the treatment of grafts prior to transplantation using TGF-.beta.
EP0572478B1 (en) 1991-02-22 2005-09-07 The Walter And Eliza Hall Institute Of Medical Research Hbgad and higad polypeptides and nucleic acids and their use for the diagnosis and treatment of gad autoantigen associated diseases
US6149909A (en) 1995-06-23 2000-11-21 Women's And Children's Hospital Synthetic α-L-iduronidase and genetic sequences encoding same
JPH07506810A (ja) * 1992-02-10 1995-07-27 デューク・ユニバーシティ 自己抗原である病原性のｔ細胞エピトープおよびｂ細胞エピトープに対する寛容性を誘導するための合成ペプチドの使用
US5747034A (en) 1992-07-09 1998-05-05 Chiron Corporation Methods and materials for the induction of T cell anergy
US5597563A (en) * 1992-09-04 1997-01-28 Beschorner; William E. Method induction of antigen-specific immune tolerance
AU716056B2 (en) * 1995-01-31 2000-02-17 Rockefeller University, The Identification of DEC, (dentritic and epithelial cells, 205 kDa), a receptor with C-type lectin domains, nucleic acids encoding DEC, and uses thereof
JP2001511187A (ja) 1997-02-28 2001-08-07 エンゾー セラピュウティクス， インコーポレイテッド 選択的免疫ダウンレギュレーション（ｓｉｄｒ）を行う新規プロセス
US6426208B1 (en) * 1999-11-12 2002-07-30 Harbor-Ucla Research And Education Institute Recombinant α-L-iduronidase, methods for producing and purifying the same and methods for treating diseases caused by deficiencies thereof
US20020014242A1 (en) * 2000-07-31 2002-02-07 Abraham Scaria Use of rapamycin to inhibit immune response and induce tolerance to gene therapy vector and encoded transgene products
US20050191309A1 (en) * 2002-05-06 2005-09-01 Kakkis Emil D. Induction of antigen specific immunologic tolerance

Also Published As

Publication number Publication date
EP1507555A4 (en) 2009-07-15
ES2401681T3 (es) 2013-04-23
US7485314B2 (en) 2009-02-03
EP1507555A2 (en) 2005-02-23
ZA200409787B (en) 2006-07-26
US20090238818A1 (en) 2009-09-24
CN1652814A (zh) 2005-08-10
TW200400045A (en) 2004-01-01
TWI349556B (en) 2011-10-01
IL165016A (en) 2012-01-31
MXPA04009292A (es) 2005-06-08
WO2003094840A2 (en) 2003-11-20
AU2003228829A1 (en) 2003-11-11
AU2003228829B2 (en) 2009-05-21
WO2003094840A3 (en) 2004-03-11
JP4933042B2 (ja) 2012-05-16
EP1507555B1 (en) 2012-12-19
BR0309809A (pt) 2007-01-09
AR039882A1 (es) 2005-03-09
IL165016A0 (en) 2005-12-18
CA2492394A1 (en) 2003-11-20
CN100360182C (zh) 2008-01-09
JP2005530762A (ja) 2005-10-13
US20030211113A1 (en) 2003-11-13
US7883707B2 (en) 2011-02-08
US20040009906A1 (en) 2004-01-15
HK1081438A1 (en) 2006-05-19

Similar Documents

Publication Publication Date Title
UY27795A1 (es) Inducción de tolerancia inmunológica específica de antígeno
AR117007A2 (es) Región constante de anticuerpo mutante
Van Niel et al. Intestinal epithelial exosomes carry MHC class II/peptides able to inform the immune system in mice
CY1123299T1 (el) Ανοσοενισχυτικη μηνιγκιτιδοκοκκικη πρωτεϊνη προσδεσης παραγοντα η
CY1108597T1 (el) Συνθεσεις που περιεχουν παραγοντα συνδεσης υποδοχεα οχ-40 ή νουκλεϊνικο οξυ που κωδικοποιει αυτον και μεθοδοι για αυξηση της αντιγονου-ειδικης ανοσοαποκρισης
CO6150189A2 (es) Vacunas para malaria
BR112013002940A2 (pt) adjuvantes de nova vacina baseados no direcionamento dos adjuvantes para os anticorpos diretamente às células que apresentam antígenos
CL2012002431A1 (es) Composición inmunogénica que comprende al menos 0,2 µg de proteína recombinante orf2 del circovirus porcino de tipo 2 (pcv2) por dosis y un adyuvante seleccionado de ácido acrílico, ácido metacrílico y cualquier polímero de los mismos, la cual es efectiva para disminuir los síntomas clínicos asociados con una infección pcv2.
SI2484375T1 (en) A vaccine composition comprising a synthetic adjuvant
AR085633A1 (es) Coadyuvantes basados en anticuerpos que son dirigidos directamente a las celulas presentadoras en antigenos
CO6230999A2 (es) Anticuerpo anti-esclerostina
RU2015103460A (ru) Ковалентно связанные конъюгаты антиген-антитело
ECSP10010370A (es) Preparacion de solucion que contiene anticuerpos en una alta concentracion
ES2138102T3 (es) Procedimiento para la deteccion de antigeno urinario asociado a tumores.
WO2006052668A3 (en) Induction of antigen specific immunologic tolerance
Yang et al. Risk factors for graft-versus-host disease after transplantation of hematopoietic stem cells from unrelated donors in the China marrow donor program
AR087654A1 (es) METODO DIAGNOSTICO DE ANIMALES VACUNADOS CON PESTIVIRUS QUIMERICO EN EL CUAL LA PROTEINA Eʳⁿˢ DEL VIRUS DE LA DIARREA VIRAL BOVINA (BVDV) ES REMPLAZADA POR PROTEINA Eʳⁿˢ DE PESTIVIRUS DE ANTILOPE AMERICANO
EA200800917A1 (ru) Адъюванты для вакцин
CO6341568A2 (es) Composicion inmunologica
Bianchi et al. Hepatitis C and autoreactivity
Kruit et al. Interleukin-2-induced thyroid dysfunction is correlated with treatment duration but not with tumor response.
Eleftheriadis et al. Suppression of humoral immune response to hepatitis B surface antigen vaccine in BALB/c mice by 1-methyl-tryptophan co-administration
AR074273A1 (es) Composicion inmunigenica de multiples componentes para la prevencion de la enfermedad estreptococica beta-hemolitica bhs. uso. metodo
RU2012108322A (ru) Способ профилактики тромботических осложнений беременности у женщин с недифференцированными формами мезенхимальной дисплазии
Yu et al. Hepatitis B seropositive status in recipients or donors is not related to worse outcomes after haploidentical hematopoietic stem cell transplantation

Legal Events

Date Code Title Description
109 Application deemed to be withdrawn

Effective date: 20160525